Polypid Ltd Dossier - Source-backed chat

Polypid Ltd

PYPDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.26

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.37Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $109.1M

Enterprise Value $104.3M

Shares Outstanding 20.3M diluted

Next Earnings Date31 Mar 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

PolyPid Ltd. is a late-stage biopharmaceutical company transitioning from clinical development to regulatory review and commercial readiness. The company's investment thesis is anchored on its lead asset, D-PLEX100, a localized, controlled-release doxycycline formulation designed to prevent surgical site infections (SSIs) following colorectal surgery. D-PLEX100 successfully met its primary and key secondary endpoints in the pivotal Phase 3 SHIELD II trial, demonstrating a clinically meaningful 60% relative risk reduction in SSIs compared to standard of care. With the rolling NDA submission completed on June 1, 2026, and a potential PDUFA target action date in Q1 2027, PolyPid is highly de-risked from a clinical perspective. However, the company remains pre-revenue and has a limited cash runway extending only into the second half of 2026, making near-term commercial partnership execution or capital raising critical to fund pre-launch activities.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$12.00

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$9.0020%

The FDA issues a Complete Response Letter (CRL) or requests additional clinical data, delaying approval. Commercial partnership discussions stall, forcing the company to execute highly dilutive equity financing at depressed valuations to sustain operations. Market adoption is slow due to hospital cost-containment policies and intense competition from standard systemic antibiotics.

Base CaseCentral scenario

$12.0050%

Matches the consensus mean

D-PLEX100 is approved by the FDA in Q1 2027. PolyPid finalizes a U.S. commercial partnership in late 2026, providing non-dilutive funding that extends the cash runway through launch. The company raises moderate additional capital through disciplined equity or warrant exercises to support global operations, while preparing for an EMA MAA submission in Q3 2026.

Bull CaseUpside scenario

$14.0030%

The FDA grants Priority Review and approves D-PLEX100 by early 2027. PolyPid secures a highly lucrative U.S. commercial partnership with substantial upfront and milestone payments, fully resolving its cash runway concerns. Rapid market adoption in the U.S. colorectal surgery market (addressing a multi-billion dollar TAM) drives strong royalty streams, and the company successfully expands the PLEX platform into other surgical and metabolic indications.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Robust Phase 3 Data: The SHIELD II trial demonstrated a statistically significant 60% relative risk reduction in SSIs (p=0.0013) and a 64% reduction in clinically significant wound infection severity (ASEPSIS score >20).
Regulatory Tailwinds: D-PLEX100 holds FDA Breakthrough Therapy, Fast Track, and QIDP designations, supporting eligibility for Priority Review and a potential 6-month review timeline.
Completed NDA Submission: The rolling NDA submission was successfully completed on June 1, 2026, shifting the asset to the regulatory decision stage.
Debt-Free Balance Sheet: PolyPid fully repaid its remaining $0.8 million venture loan facility in early May 2026, leaving the company with no outstanding loan-related liabilities.

Key Investment Risks

Limited Cash Runway: With $10.9 million in cash and short-term deposits as of March 31, 2026, the company's resources are only sufficient to fund operations into the second half of 2026.
Regulatory Approval Uncertainty: Despite strong Phase 3 data, regulatory approval is never guaranteed, and any delay or CRL would severely impact the company's valuation.
Commercial Execution and Financing Risk: As a pre-revenue entity, PolyPid is highly dependent on securing a commercial partner or raising additional capital to fund pre-launch and launch activities.

Thesis Invalidation Triggers

FDA refusal to file or accept the NDA submission for review.
Failure to secure a U.S. commercial partnership or alternative financing by the end of 2026, leading to a severe liquidity crisis.
A regulatory demand for an additional clinical trial prior to approval.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.